Company intelligence / Profile preview
Delpor
San Francisco, California, United Statesdelpor.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Delpor is developing once-yearly therapies for chronic conditions using its Prozor™ implantable drug delivery platform. The lead asset is a 6–12 month formulation of risperidone for schizophrenia, with other programs targeting CNS and chronic diseases. Clinical data supports sustained, consistent drug release with improved adherence and safety profile due to smoother pharmacokinetics. The company has multiple assets in development but no approved products yet
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculeProteinPeptidesBiologic (as a group for proteins/peptides)Device (drug-device combination)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Delpor.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Delpor.